



# Survival-based bioinformatics analysis to identify hub genes and key pathways in non-small cell lung cancer

Chunliang Liu<sup>1</sup>, Yu Chen<sup>2</sup>, Yuqi Deng<sup>2</sup>, Yu Dong<sup>2</sup>, Jixuan Jiang<sup>2</sup>, Si Chen<sup>1</sup>, Wenfeng Kang<sup>1</sup>, Jiong Deng<sup>1</sup>, Haipeng Sun<sup>1</sup>

<sup>1</sup>Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; <sup>2</sup>Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

**Contributions:** (I) Conception and design: H Sun, J Deng; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: C Liu, S Chen, Y Chen, Y Deng, Y Dong, J Jiang, W Kang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Jiong Deng; Haipeng Sun. Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Email: jiongdeng@shsmu.edu.cn; sunhaipeng@shsmu.edu.cn.

**Background:** Lung cancer is one of the leading causes of cancer mortality worldwide. Here, we performed an integrative bioinformatics analysis to screen hub genes and critical pathways in non-small cell lung cancer (NSCLC) based on the overall survival rate of differentially expressed genes (DEGs).

**Methods:** Four datasets from the gene expression omnibus (GEO) were used to identify the DEGs. To obtain robust DEGs in NSCLC, only the DEGs that co-existed in the four datasets were selected for subsequent analysis. To identify the genes correlated with overall survival, the overall survival of these genes was then analyzed using the Kaplan-Meier plotter database. The genes significantly correlated with survival were used to perform gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analysis; next, these genes were used to construct a protein-protein interaction network. MCODE and CytoHubba were used to identify the clusters and hub genes. Finally, the hub genes were validated in the Cancer Genome Atlas (TCGA) and the Human Protein Atlas (HPA).

**Results:** We found 522 up-regulated DEGs, and 989 down-regulated DEGs between the NSCLC and normal lung tissue, and 895 of them were correlated with a higher overall survival. GO analysis showed that the DEGs that were associated with a higher overall survival were enriched in cell division, cell cycle, DNA replication, angiogenesis, and cell migration. KEGG analysis was consistent with GO analysis and showed that p53 signaling pathway, pyrimidine metabolism, cGMP-PKG signaling pathway and renin secretion pathway were associated with overall survival in NSCLC. In the protein-protein analysis, we identified seven clusters and six hub genes which were *BUB1B*, *CCNB1*, *CENPE*, *KIF18A*, *NDC10*, and *MAD2L1*. Of these genes, *CENPE* and *KIF18A* had not been reported until now. Finally, the dysregulated expression of the six hub genes was validated by the data from the TCGA and HPA.

**Conclusions:** We identified the hub genes and potential mechanisms of NSCLC based on multiple-microarray analysis and overall survival; then, validated the hub genes in the TCGA and HPA database. These hub genes may serve as potential therapeutic targets.

**Keywords:** Non-small cell lung cancer (NSCLC); multiple microarray analysis; differentially expressed genes (DEGs); overall survival; hub genes; potential mechanism

Submitted Feb 12, 2019. Accepted for publication May 21, 2019.

doi: 10.21037/tcr.2019.06.35

View this article at: <http://dx.doi.org/10.21037/tcr.2019.06.35>

## Introduction

Lung cancer is the most prevalent cancer and the leading cause of cancer-associated death (1). Recent global cancer statistics report that the number of new lung cancer cases was 2,093,876 (11.6% of the total cases), and the number of deaths was 1,761,007 (18.4% of the total cancer deaths) in 2018 (2).

Lung cancer can be classified into small cell lung cancer (SCLC, 15% of cases) and NSCLC (85% of cases) based on histopathologic diagnosis (3-5). For non-small cell lung cancer (NSCLC), the 5-year survival rates are about 4–17% mainly depending on stage (3-5). Mechanisms underlying NSCLC have been intensively investigated in the past decades. Abnormal expression or mutation of genes such as epidermal growth factor receptor (*EGFR*) and tumor suppressor protein 53 (*TP53*) play essential roles in carcinogenesis, progression, and metastasis of NSCLC (3-6). However, the molecular interaction mechanisms and dysregulated pathways remain unclear.

High-throughput technologies such as microarray or RNA-seq allow researchers to detect the gene expression profiles at a global level (7-10). Based on this technology, new hub genes that play essential roles in the pathology of NSCLC have been identified (11,12). However, all of these pieces of research were based on a single dataset analysis, which might have led to biased results. Here, we have screened the hub genes based on multiple-microarrays and overall survival, and, in doing so, have made new discoveries.

## Methods

### *Gene expression dataset*

Four NSCLC mRNA microarray datasets (GSE18842, GSE19188, GSE27262, and GSE33532) were downloaded from the National Center of Biotechnology Information Gene Expression Omnibus database (<http://www.ncbi.nlm.nih.gov/geo/>), which is the most significant resource for high throughput data submitted by scientists under strict standards. These datasets were based on the GPL570 platform (Affymetrix Human Genome U133 Plus 2.0 Array). Each dataset contained tumor samples and adjacent healthy tissue samples and were each validated by their submitter. The datasets and their accompanying sample counts are as follows: 46 tumor samples and 45 normal samples for GSE18842, 91 tumor samples and 65 normal samples for GSE19188, 25 tumor samples and 25 normal

samples for GSE27262, and 80 tumor samples and 20 normal samples for GSE33532.

### *Screening differentially expressed genes (DEGs)*

The R software (version 3.4.0) and Bioconductor packages were used to analyze the microarray datasets (13). The process for analysis was as follows: we imported CEL files using the *affy* package, assessed the microarray data quality using the *simpleaffy* package, preprocessed the raw data into expression metrics using the robust multi-array average (RMA) algorithm in the *gcrma* package, and used the *genefilter* package to filter the probe with low sensitivity before comparison (14-16); the *t*-test then analyzed the DEGs between the tumor and normal group samples based on the *limma* package (17); multiple testing was corrected by the Benjamini-Hochberg method to obtain the adjusted P-value; finally, the genes with adjusted  $P < 0.001$  and  $|\log_2(\text{fold-change (FC)})| > 1$  were selected as the candidate DEGs. To further enhance the reliability of the DEG analysis, the overlapping DEGs co-existing in all four datasets were identified using *FunRich* software (version 3.1.3) (18).

### *Screening overlapping DEGs correlated with overall survival in the Kaplan-Meier plotter database*

An online global survival database Kaplan-Meier plotter (<http://kmplot.com/analysis/>), which contains both the survival data and gene expression data of breast, gastric, ovarian and lung cancers, was used to evaluate the correlation between the prognostic significance and each DEGs of NSCLC (19). The patient samples were classified into high and low expression groups by the median expression value of a gene. In our study, we used the default parameters, which in brief, presented no subtypes restrictions in the “univariate” for Cox regression and the “exclude biased arrays” for array quality control. For each gene, the log-rank P value and median survival were calculated. The gene with log-rank P value  $< 0.001$  were considered to be statistically significant.

### *Function enrichment analysis of DEGs correlated with overall survival*

Both Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis are widely used to identify functions

and pathways for a large number of genes. Here, we used a professional, comprehensive R package clusterProfiler to investigate enriched GO biological processes and KEGG pathways of the overlapping DEGs correlated with overall survival. The cut-off criterion was set at Benjamini-Hochberg adjusted  $P < 0.05$  and  $q < 0.05$  (20).

### ***PPI network construction and hub gene analysis***

The protein-protein interactions played an essential role in regulating biological processes. These kinds of relationship can be presented by a PPI network in which vertices represent proteins, and edges represent the interaction between proteins. The densely connected regions may serve the enriched function clusters. The proteins are shown to have a high connection (interaction) with several other proteins suggesting a central regulatory role, likely to be regulatory “hubs” (21).

To gain the protein-protein interaction information, the DEGs correlated with overall survival were imported into the STRING database to construct a PPI network. The confidence score cutoff was set as 0.9, and only the interaction information validated by experiment was adopted to increase the confidence. Then, the interaction information was imported into the Cytoscape software (version 3.6.1) (22). MCODE was used to explore densely connected regions in large protein-protein interaction networks and the scores  $>4$  and nodes  $>5$  were set as the cutoff criteria (23). ClusterProfiler package was used to analyze the functions of the clusters. CytoHubba was used to reveal the hub nodes in the regulation network (24). The overlapping genes in the top 10 calculated by degree and maximal clique centrality (MCC) were selected as hub genes. Then, we identified their expression level in their original datasets.

### ***Validation of hub genes in the Cancer Genome Atlas (TCGA) and Human Protein Atlas (HPA) database***

The mRNA level and overall survival of hub genes were validated by TCGA data. The RNA-seq data was downloaded and analyzed by TCGAbiolinks package in R (25,26). The overall survival analysis of TCGA data was performed using the GEPIA online tool (27). The protein level in healthy tissue and lung cancer tissue was validated using the immunohistochemical data of the HPA database (28).

## **Results**


### ***Screening DEGs correlated with overall survival in a K-M plotter database***

To find DEGs of NSCLC, we selected four mRNA microarrays from the GEO database for further analysis.  $|\log FC| > 1$  and adjust P value  $< 0.001$  were set as a strict cutoff to avoid false positive results. After analysis, we obtained 4,216 DEGs (1,873 up-regulated and 2,253 down-regulated) in GSE18842, 3,114 DEGs (1,134 up-regulated and 1,980 down-regulated) in GSE19188, 3,035 DEGs (1,334 up-regulated and 1,701 down-regulated) in GSE27262, and 3,689 DEGs (1,565 up-regulated and 2,124 down-regulated) in GSE33532. As shown in the gene expression heatmaps (*Figure 1A,B,C,D*), in each dataset these DEGs showed distinct expression patterns between normal samples and tumor samples. To obtain robust DEGs in NSCLC, we performed Venn diagrams (*Figure 1E,F*) of up-regulated DEGs and down-regulated DEGs between each of the four datasets, and found 522 up-regulated DEGs and 989 down-regulated DEGs. These genes were considered as the DEGs of NSCLC for further analysis.

To find out how these DEGs were correlated with overall survival, we put these DEGs into the K-M plotter database to analyze the median survival and log-rank p-value between the low expression cohort and the high expression cohort. DEGs with (log rank P)  $< 0.001$  were considered as DEGs correlated with overall survival (DEGOSs). After screening, we obtained 895 DEGOSs, among which 265 genes were up-regulated and 630 genes were down-regulated (*Table 1* and online: <http://fp.amegroups.cn/cms/tcr.2019.06.35-1.pdf>). Importantly, high expression of up-regulated genes was significantly correlated with poor overall survival while the low expression of down-regulated genes was correlated with poor overall survival of patients (*Table 1* and online: <http://fp.amegroups.cn/cms/tcr.2019.06.35-1.pdf>).

### ***Function analysis of DEGOSs***

To get insight into the function of DEGOSs, we performed GO enrichment analysis; the top 10 biological processes with statistical significance were shown in *Figure 2A,B*. The dysregulated genes of each pathway were listed in the *Table S1*. The upregulated genes enriched in the biological processes that associated with cell division, organelle division and chromosome division. The downregulated genes were enriched in the biological processes associated



**Figure 1** Screening the differentially expressed genes. (A,B,C,D) The differentially expressed genes profiles of four datasets. The green bar represents normal sample, and the orange bar represents tumor sample. (E,F) The Venn diagrams of up-regulated genes and down-regulated genes, respectively.


with angiogenesis and negative regulation of cell migration. The angiogenesis switch was governed by the countervailing factors that either induce or oppose angiogenesis (29,30). In this study, we found most angiogenesis inhibitors (*MMRN2*, *RECK*, *ANGPT1*, *PECAM1*, *ROBO4* and *S1PR1*) and HIF 1 $\alpha$  inhibitor (*KLF2*) were downregulated and enriched in the angiogenesis biological process (31-36). This indicated the angiogenesis inhibited switch was downregulated in the NSCLC.

For a further exploration of the dysregulated pathways influenced by the DEGOSs, we performed the KEGG pathway enrichment (Figure 2C,D and Table S2). The upregulated genes were enriched in the KEGG pathways associated with DNA replication and cell cycle, while the downregulated genes were enriched in the KEGG pathways

associated with cell adhesion and cell migration. This was consistent with the GO enrichment analysis.

#### *PPI network construction and cluster analysis*


The PPI network provided a convenient method to visualize the protein-protein interactions and find the potential molecular mechanism. The PPI network was composed of DEGOSs in which we found 7 function clusters ranked by scores. We performed a GO analysis of each cluster to define its function (Figure 3 and Table S3). Cluster 1 and cluster 4 took part in the cell division mainly by chromosome segregation and organelle fusion. Cluster 2 seemed to have a function in blood coagulation. Cluster 3 and cluster 7 were functionally enriched in the G-protein




**Figure 2** The Gene Ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analysis of differentially expressed genes correlated with overall survival. (A,B) The top 10 upregulated and downregulated Gene ontology biological process terms with statistical significance. (C,D) The upregulated and downregulated KEGG pathways with statistical significance (adjusted  $P < 0.05$ ).

**Table 1** Five representative up- or down-regulated DEGs correlated with overall survival

Gene symbol	Median survival (month)		Log rank P	Hazard ratio
	Low expression cohort	High expression cohort		
<b>Upregulated genes</b>				
<i>ASPM</i>	96	43.83	<1E-16	1.76 (1.55–2.01)
<i>CDC20</i>	96	42.8	<1E-16	1.82 (1.6–2.07)
<i>TPX2</i>	96.2	42	<1E-16	1.87 (1.64–2.12)
<i>KIF2C</i>	96.1	44	<1E-16	1.78 (1.57–2.03)
<i>DLGAP5</i>	94.5	43.83	<1E-16	1.73 (1.52–1.97)
<b>Downregulated genes</b>				
<i>CPED1</i>	45.47	125	<1E-16	0.66 (0.56–0.77)
<i>SYNE1</i>	44	95.5	<1E-16	0.68 (0.6–0.75)
<i>CBX7</i>	42.23	91	<1E-16	0.53 (0.47–0.59)
<i>PTEN</i>	48	124	<1E-16	0.96 (0.82–1.12)
<i>PPM1K</i>	46	134	<1E-16	0.65 (0.56–0.77)



**Figure 3** A–G represent the cluster 1–7. The nodes represent the protein. The edges represent the interaction between the proteins.



**Figure 4** A represents the six hub genes and their interaction.

coupled receptor signaling pathway. Cluster 4 played a role in the G2/M transition in the cell cycle. Cluster 5 had the only protein poly-ubiquitination with statistical significance. These clusters provided an overview of the potential molecular mechanisms in NSCLC by bioinformatics and may help us to understand the pathogenesis of NSCLC.

#### Hub gene identification

Hub genes are highly interconnected genes and play central roles in the PPI network. They have the potential to be biomarkers and therapeutic targets. To obtain a robust result, we calculated the degree and MCC scores for each node. The top 10 in both algorithms were selected as hub genes and used to construct PPI networks to visualize the interaction. We identified six hub genes which were *BUB1B*, *CCNB1*, *CENPE*, *KIF18A*, *MAD2L1*, and *NDC80* (Figure 4). All these genes had a function associated with chromosome and spindle behavior of mitotic cell division and showed an up-regulated expression level in NSCLC tissue (Table S4) (37-39).

#### Validation of hub genes in TCGA and HPA


To validate whether the hub genes identified above were of universal significance, we analyzed their mRNA expression level and overall survival in TCGA lung cancer RNA-seq data and protein level in HPA immunohistochemical data. We found that all these hub genes were abnormally up-regulated expressed (Figure 5A,B,C,D,E,F), and the protein level was up-regulated consistently with mRNA level, as shown in Figure 5G. They were also correlated with overall

survival (Figure 6). This evidence gives support to the universal significance of our results.


#### Discussion

In our study, we explored the hub genes and potential mechanisms based on the DEGs correlated with overall survival in NSCLC for the first time. We found that cell division, cell cycle, cell migration, DNA replication, and angiogenesis might be the major dysregulated functions in NSCLC. P53 signaling pathway and cGMP-PKG signaling pathway might be the major dysregulated signaling pathways. Furthermore, there were six genes associated with cell division that were identified as hub genes. Finally, we performed an independent validation of hub genes in TCGA and HPA and found that these hub genes did show abnormal expression patterns in NSCLC and correlated with overall survival of NSCLC patients.

In our function analysis, we found the upregulated genes enriched in the cell division, cell cycle and chromosome segregation process. Spindle assembly checkpoint played important roles in these processes. And the hub genes were the key components of the spindle assembly checkpoint. The downregulated genes enriched in the negative regulation of cell migration and angiogenesis. In the cell migration process, cell adhesion molecules like JAM2 and PECAM1 were downregulated to break the cell junction and increased cell motility (33,40). In the angiogenesis process, key inhibitors of several angiogenic switch were downregulated. ANGPT1/TEK and ROBO4/SLIT2 were both the receptor/ligand system to promote the vascular stability in the physiological condition (32,35,36,41-43). Many clinical studies showed that *ANGPT1* and *TEK* expression level was downregulated in the NSCLC tissue and loss of ANGPT1/TEK system increased metastasis and angiogenesis in the mice model (32,44,45). But the mechanism was still to be clarified. ROBO4/SLIT2 system suppressed the tumor growth and metastasis through the tumor angiogenesis in breast cancer (41). SLIT2 could suppress cell migration by the  $\beta$ -catenin and the AKT-GSK3 $\beta$  signaling pathway in colorectal cancer (42). The downregulation of *SLIT2* expression was also observed in the clinical lung cancer patient cases (44,45). In vitro experiment showed that SLIT2 could promote the NSCLC cells metastasis to the brain by downregulating the *CDH2*. The KEGG pathway enrichment results were consistent with GO analysis. The NSCLC tissue showed upregulated



**Figure 5** The validation of the mRNA expression level and the protein expression level of hub genes. (A,B,C,D,E,F) The mRNA expression level of six hub genes in the Cancer Genome Atlas (TCGA); (G) the protein level of the four hub genes that were found in Human Protein Atlas (HPA).



**Figure 6** The overall survival of six hub genes in the Cancer Genome Atlas (TCGA) database.



pathways associated with cell division and DNA replication and downregulated pathways involved of cell adhesion and negative regulation of cell migration. The KEGG analysis also provided a new clue that renin secretion pathway might have some special roles in the NSCLC progress. Many reports showed ACE protein and mRNA level was decreased and associated with the angiogenesis and tumor growth in the NSCLC patients (46,47). But the molecular mechanism had not been reported.

In the six hub genes, *CENPE* and *KIF18A* were identified for the first time. Both of these are kinesins superfamily members that take part in the mitotic spindle (48,49). The mitotic spindle is a popular drug target validated in cancer chemotherapy. Taxanes and vinca alkaloids, which target the tubulin in mitotic spindle, have been used in successful clinical application (49). Centromeric protein E (*CENPE*) is a kinesin-like motor protein that establishes and maintains the connection between spindle microtubules and chromosomes and shifts the chromosomes to the metaphase plate powered by ATPase activity. It is required for the transformation from the metaphase to the anaphase. Aurora B and protein phosphate 1 control the phosphorylation and dephosphorylation of *CENPE* to modulate its operation, which is essential for chromosome congression. *BUB1B* also controls its action at the kinetics as a mitotic checkpoint event (49,50).

The protein level of *CENPE* should kept in balance to maintain cell division. Up-regulation of *CENPE* has been reported with a worse overall survival in breast cancer (51), but down-regulation of *CENPE* has been found in liver cancer (50). However, reports about *CENPE* in NSCLC are rare. Due to the importance of *CENPE*, it is considered a drug target in cancer therapy. There are three inhibitors of *CENPE* that showed good effects (50). *GSK923295* is an allosteric inhibitor of *CENPE* kinesin motor ATPase activity that induced tumor cell apoptosis and tumor regression. In the phase I clinical study which involved 39 refractory cancer patients (including 4 NSCLC patients), *GSK923295* exhibited dose-proportional pharmacokinetics with a low incidence of myelosuppression and neuropathy. *PF-2271* is a highly specific *CENPE* motor activity which shows no inhibition of protein kinase and ATPase activity of highly related kinesins. It inhibits basal-like breast cancer cell survival without inhibition to normal breast epithelial cells. Despite this, there is no report about the effect of *PF-2271* in NSCLC. Compound A is a *CENPE* ATPase inhibitor showed a time-dependent anti-proliferative activity. It has been proved to inhibit the proliferation of

multiple lung cancer cell lines. *KIF18A* takes part in the chromosome congression by reducing the amplitude of preanaphase oscillations and slowing poleward movement during anaphase. It has been reported that *KIF18A* is overexpressed in colorectal cancer and its overexpression is also correlated with the grade, metastasis and worse survival in breast cancer (52-54). There still is no report about *KIF18A*. *BTB-1* has been the only inhibitor of *KIF18A* known until now. However, it has shown a high specificity and inhibition effect to *KIF18A* (50). Based on the clues above and the high correlation with NSCLC survival, we think *CENPE* and *KIF18A* are worthy of further study and may serve as therapeutic targets in NSCLC.

In summary, we identified some new pathways and two new hub genes in NSCLC based on the DEGs correlated with overall survival. The two hub genes, *CENPE* and *KIF18A*, are associated with solid tumors, and the inhibitor of *CENPE* in the phase I clinical study. Hub gene screening based on survival might be more clinically significant, and our method might be more powerful. However, hub gene function in NSCLC still needs further investigation.

### Acknowledgments

**Funding:** This work was supported by Ministry of Science and Technology of China (2012BAI02B05 and 2013YQ030923), National Natural Science Foundation of China (NSFC81570717 and 81522011), and Science and Technology Commission of Shanghai Municipality (13ZR1423300 and 16JC1404400).

### Footnote

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/tcr.2019.06.35>). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The institutional ethical approval and informed consent were waived.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons

Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

- Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. *Nat Rev Dis Prim* 2015;1:15009.
- Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2018;68:394-424.
- Herbst RS, Heymach JV, Lippman SM. Lung cancer. *N Engl J Med* 2008;359:1367-80.
- Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. *Lancet* 2017;389:299-311.
- Chen Z, Fillmore CM, Hammerman PS, et al. Non-small-cell lung cancers: A heterogeneous set of diseases. *Nat Rev Cancer* 2014;14:535-46.
- Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. *Lancet Oncol* 2015;16:e342-51.
- Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. *Oncogene* 2003;22:6497-507.
- Broadhead ML, Clark JCM, Dass CR, et al. Microarray: An instrument for cancer surgeons of the future?: Surgical science. *ANZ J Surg* 2010;80:531-6.
- Jin B, Wang W, Du G, et al. Identifying hub genes and dysregulated pathways in hepatocellular carcinoma. *Eur Rev Med Pharmacol Sci* 2015;19:592-601.
- Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. *J Thorac Cardiovasc Surg* 1999;118:1136-52.
- Tang Q, Zhang H, Kong M, et al. Hub genes and key pathways of non-small lung cancer identified using bioinformatics. *Oncol Lett* 2018;16:2344-54.
- Tian ZQ, Li ZH, Wen SW, et al. Identification of Commonly Dysregulated Genes in Non-small-cell Lung Cancer by Integrated Analysis of Microarray Data and qRT-PCR Validation. *Lung* 2015;193:583-92.
- Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* 2004;5:R80.
- Gautier L, Cope L, Bolstad BM, et al. affy--analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics* 2004;20:307-15.
- Olson NE. The Microarray Data Analysis Process: From Raw Data to Biological Significance. *NeuroRx* 2006;3:373-83.
- Brettschneider J, Bolstad B, Collin F, et al. Quality assessment for short oligonucleotide microarray data. *Technometrics* 2008;50:241-64.
- Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;43:e47.
- Pathan M, Keerthikumar S, Ang CS, et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool. *Proteomics* 2015;15:2597-601.
- Györfy B, Surowiak P, Budczies J, et al. Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer. *PLoS One* 2013;8:e82241.
- Yu G, Wang LG, Han Y, et al. clusterProfiler: An R Package for Comparing Biological Themes Among Gene Clusters. *OMICS* 2012;16:284-7.
- Jin B, Wang W, Du G, et al. Identifying hub genes and dysregulated pathways in hepatocellular carcinoma. *Eur Rev Med Pharmacol Sci* 2015;19:592-601.
- Shannon P, Markiel A, Ozier O, et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. *Genome Res* 2003;13:2498-504.
- Pruitt KD, Hogue CW, Groll M, et al. An automated method for finding molecular complexes in large protein interaction networks. *Nucleic Acids Res* 2001;29:137-40.
- Chin CH, Chen SH, Wu HH, et al. cytoHubba: Identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* 2014;8:S11-7.
- Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge. *Contemp Oncol (Pozn)* 2015;19:A68-77.
- Colaprico A, Silva TC, Olsen C, et al. TCGAAbilinks: An R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Res* 2016;44:e71.
- Tang Z, Li C, Kang B, et al. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* 2017;45:W98-102.
- Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human Protein Atlas. *Nat Biotechnol* 2010;28:1248-50.

29. Rao N, Lee YF, Ge R. Novel endogenous angiogenesis inhibitors and their therapeutic potential. *Acta Pharmacologica Sinica* 2015;36:1177-90.
30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646-74.
31. Alexius-Lindgren M, Andersson E, Lindstedt I, et al. The RECK gene and biological malignancy--its significance in angiogenesis and inhibition of matrix metalloproteinases. *Anticancer Res* 2014;34:3867-73.
32. Michael IP, Orebrand M, Lima M, et al. Angiopoietin-1 deficiency increases tumor metastasis in mice. *BMC Cancer* 2017;17:539.
33. Park S, Sorenson CM, Sheibani N, et al. PECAM-1 isoforms, eNOS and endoglin axis in regulation of angiogenesis. *Clin Sci (Lond)* 2015;129:217-34.
34. Xie Z, Liu H, Geng M. Targeting sphingosine-1-phosphate signaling for cancer therapy. *Sci China Life Sci* 2017;60:585-600.
35. Enomoto S, Mitsui K, Kawamura T, et al. Suppression of Slit2/Robo1 mediated HUVEC migration by Robo4. *Biochem Biophys Res Commun* 2016;469:797-802.
36. Novodvorsky P, Chico TJ. The Role of the Transcription Factor KLF2 in Vascular Development and Disease. *Prog Mol Biol Transl Sci* 2014;124:155-88.
37. Chen H, Lee J, Kljavin NM, et al. Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinoma. *Genes Cancer* 2015;6:106.
38. Zhang LL, Feng ZL, Su MX, et al. Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells. *Eur J Pharmacol* 2018;830:17-25.
39. Shi YX, Zhu T, Zou T, et al. Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma. *Oncotarget* 2016;7:85235-43.
40. Wang Y, Yu L, Wang T. MicroRNA-374b inhibits the tumor growth and promotes apoptosis in non-small cell lung cancer tissue through the p38/ERK signaling pathway by targeting JAM-2. *J Thorac Dis* 2018;10:5489-98.
41. Zhao H, Ahirwar DK, Oghumu S, et al. Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis. *Mol Oncol* 2016;10:272-81.
42. Chen WF, Gao WD, Li QL, et al. SLIT2 inhibits cell migration in colorectal cancer through the AKT-GSK3 $\beta$  signaling pathway. *Int J Colorectal Dis* 2013;28:933-40.
43. Chang PH, Hwang-Verslues WW, Chang YC, et al. Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/ $\beta$ -catenin pathway. *Cancer Res* 2012;72:4652-61.
44. Piao J, Sun J, Yang Y, et al. Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis. *Gene* 2018;647:306-11.
45. Metodieva SN, Nikolova DN, Cherneva RV. Expression analysis of angiogenesis-related genes in Bulgarian patients with early-stage non-small cell lung cancer. *Tumori* 2011;97:86-94.
46. Goldstein B, Trivedi M, Speth RC. Alterations in Gene Expression of Components of the Renin-Angiotensin System and Its Related Enzymes in Lung Cancer. *Lung Cancer Int* 2017;2017:6914976.
47. Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S, et al. The renin-angiotensin system meets the hallmarks of cancer. *J Renin Angiotensin Aldosterone Syst* 2015;16:227-33.
48. Silk AD, Zasadil LM, Holland AJ, et al. Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors. *Proc Natl Acad Sci* 2013;110:E4134-41.
49. Rath O, Kozielski F. Kinesins and cancer. *Nat Rev Cancer* 2012;12:527-39.
50. El-Arabey AA, Salama SA, Abd-Allah AR. CENP-E as a target for cancer therapy: Where are we now? *Life Sci* 2018;208:192-200.
51. Kung PP, Martinez R, Zhu Z, et al. Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer. *Mol Cancer Ther* 2014;13:2104-15.
52. Zhu H, Xu W, Zhang H, et al. Targeted deletion of Kif18a protects from colitis-associated colorectal (CAC) tumors in mice through impairing Akt phosphorylation. *Biochem Biophys Res Commun* 2013;438:97-102.
53. Alfarsi LH, Elansari R, Toss MS, et al. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. *Breast Cancer Res Treat* 2019;173:93-102.
54. Zhang C, Zhu C, Chen H, et al. Kif18A is involved in human breast carcinogenesis. *Carcinogenesis* 2010;31:1676-84.

**Cite this article as:** Liu C, Chen Y, Deng Y, Dong Y, Jiang J, Chen S, Kang W, Deng J, Sun H. Survival-based bioinformatics analysis to identify hub genes and key pathways in non-small cell lung cancer. *Transl Cancer Res* 2019;8(4):1188-1198. doi: 10.21037/tcr.2019.06.35

Table S1 The GO enrichment analysis

ID	Description	P adjust	Gene ID
Upregulated			
GO: 0007059	Chromosome segregation	7.38E-37	NEK2/NUSAP1/BUB1B/CENPE/SPAG5/CCNE1/PTTG1/KIF18B/TOP2A/BIRC5/MKI67/CENPN/BRIP1/KIF14/NCAPG/KIF18A/RACGAP1/CENPF/ESPL1/MAD2L1/MIS18A/ZWINT/BLM/NDC80/RCC1/CCNB1/NDE1/TUBG1/NCAPD3/KIF23/BRCA1/ECT2/FEN1/CCNE2/CDC48/CDC20/KIF2C/DLGAP5/BUB1/KIF4A/HJURP/TTK/PRC1/AURKB/TRIP13/CDT1/NCAPH/CDC6/SPC25/OIP5
GO: 0140014	Mitotic nuclear division	6.04E-34	NEK2/NUSAP1/BUB1B/CENPE/SPAG5/CCNE1/PTTG1/KIF18B/MKI67/KIF14/NCAPG/KIF18A/CCNA2/RACGAP1/CENPF/ESPL1/MAD2L1/KIF11/AURKA/ZWINT/NDC80/RCC1/CCNB1/NDE1/CCNF/TUBG1/NCAPD3/KNTC1/KIF23/CCNE2/CDC48/CDC20/TPX2/KIF2C/DLGAP5/BUB1/KIF4A/UBE2C/TTK/CCNB2/CHEK1/PRC1/AURKB/MYBL2/TRIP13/CDT1/NCAPH/CDC6
GO: 0051301	Cell division	2.92E-33	ASPM/NEK2/NUSAP1/BUB1B/CENPE/SPAG5/KIF20A/CCNE1/PTTG1/KIF18B/TOP2A/BIRC5/NCAPG2/BRIP1/KIF14/NCAPG/CCNA2/RACGAP1/CENPF/ESPL1/MAD2L1/MIS18A/HELLS/KIF11/AURKA/ZWINT/BRCA2/BLM/NDC80/MDK/RCC1/CCNB1/NDE1/CKS2/CCNF/NCAPD3/KNTC1/E2F8/KIF23/PIMREG/ECT2/CKAP2/TIMELESS/CCNE2/CDC48/CDC20/TPX2/KIF2C/BUB1/CEP55/KIF4A/UBE2C/CCNB2/PRC1/AURKB/CDC43/CDT1/NCAPH/CDC6/SPC25/OIP5
GO: 0000280	Nuclear division	3.08E-33	ASPM/NEK2/NUSAP1/BUB1B/CENPE/SPAG5/CCNE1/PTTG1/KIF18B/TOP2A/MKI67/BRIP1/KIF14/NCAPG/KIF18A/CCNA2/RACGAP1/CENPF/ESPL1/MAD2L1/KIF11/AURKA/ZWINT/BLM/NDC80/RCC1/CCNB1/NDE1/CKS2/CCNF/TUBG1/NCAPD3/KNTC1/KIF23/CCNE2/CDC48/CDC20/TPX2/KIF2C/DLGAP5/BUB1/KIF4A/UBE2C/TTK/CCNB2/CHEK1/PRC1/AURKB/MYBL2/TRIP13/CDT1/NCAPH/CDC6
GO: 0048285	Organelle fission	3.48E-31	ASPM/NEK2/NUSAP1/BUB1B/CENPE/SPAG5/CCNE1/PTTG1/KIF18B/TOP2A/MKI67/BRIP1/KIF14/NCAPG/KIF18A/CCNA2/RACGAP1/CENPF/ESPL1/MAD2L1/KIF11/AURKA/ZWINT/BLM/NDC80/RCC1/CCNB1/NDE1/CKS2/CCNF/TUBG1/NCAPD3/KNTC1/KIF23/CCNE2/CDC48/CDC20/TPX2/KIF2C/DLGAP5/BUB1/KIF4A/UBE2C/TTK/CCNB2/CHEK1/PRC1/AURKB/MYBL2/TRIP13/CDT1/NCAPH/CDC6
GO: 0098813	Nuclear chromosome segregation	3.33E-29	NEK2/NUSAP1/BUB1B/CENPE/SPAG5/CCNE1/PTTG1/KIF18B/TOP2A/BRIP1/KIF14/NCAPG/KIF18A/RACGAP1/CENPF/ESPL1/MAD2L1/ZWINT/BLM/NDC80/CCNB1/TUBG1/NCAPD3/KIF23/ECT2/FEN1/CCNE2/CDC48/CDC20/KIF2C/DLGAP5/BUB1/KIF4A/TTK/PRC1/AURKB/TRIP13/CDT1/NCAPH/CDC6
GO: 0000819	Sister chromatid segregation	3.73E-27	NEK2/NUSAP1/BUB1B/CENPE/SPAG5/PTTG1/KIF18B/TOP2A/KIF14/NCAPG/KIF18A/RACGAP1/CENPF/ESPL1/MAD2L1/ZWINT/NDC80/CCNB1/TUBG1/NCAPD3/KIF23/FEN1/CDC48/CDC20/KIF2C/DLGAP5/BUB1/KIF4A/TTK/PRC1/AURKB/TRIP13/CDT1/NCAPH/CDC6
GO: 0000070	Mitotic sister chromatid segregation	7.59E-27	NEK2/NUSAP1/BUB1B/CENPE/SPAG5/PTTG1/KIF18B/KIF14/NCAPG/KIF18A/RACGAP1/CENPF/ESPL1/MAD2L1/ZWINT/NDC80/CCNB1/TUBG1/NCAPD3/KIF23/CDC48/CDC20/KIF2C/DLGAP5/BUB1/KIF4A/TTK/PRC1/AURKB/TRIP13/CDT1/NCAPH/CDC6
GO: 0044770	Cell cycle phase transition	1.95E-24	NEK2/BUB1B/CENPE/GTSE1/CCNE1/TYMS/POLE2/MELK/KIF14/CCNA2/CENPF/MCM2/ESPL1/MAD2L1/AURKA/FGFR1OP/BLM/RPA3/NDC80/RCC1/RECQL4/CCNB1/RRM2/DONSON/NDE1/HMMR/CKS2/TUBG1/KNTC1/E2F8/PLK4/BRCA1/EZH2/CDKN2A/TIMELESS/CCNE2/CDC20/TPX2/DLGAP5/BUB1/UBE2C/TTK/CCNB2/CHEK1/AURKB/FOXM1/CDKN3/MCM4/TRIP13/CDT1/CDC6
GO: 0044772	Mitotic cell cycle phase transition	3.96E-24	NEK2/BUB1B/CENPE/GTSE1/CCNE1/TYMS/POLE2/MELK/KIF14/CCNA2/CENPF/MCM2/ESPL1/MAD2L1/AURKA/FGFR1OP/BLM/RPA3/NDC80/RCC1/RECQL4/CCNB1/RRM2/DONSON/NDE1/HMMR/CKS2/TUBG1/KNTC1/E2F8/PLK4/BRCA1/EZH2/CDKN2A/CCNE2/CDC20/TPX2/DLGAP5/BUB1/UBE2C/TTK/CCNB2/AURKB/FOXM1/CDKN3/MCM4/TRIP13/CDT1/CDC6
Downregulated			
GO: 0001525	Angiogenesis	1.87E-06	TEK/MAP3K3/MMRN2/TMEM100/ETS1/PTPRM/SOX17/RECK/PPP1R16B/DCN/CX3CR1/SASH1/NPR1/TGFBR2/AGTR1/SLIT2/GATA2/GATA6/MEOX2/PDE3B/TCF21/JAM3/EMP2/KLF2/ANGPT1/STARD13/KDR/CDH5/FGF2/PTPRB/PECAM1/HGF/S1PR1/FGF18/ROBO4/PRKCB/GJA5/EDNRA/CAV1/ARHGAP24/CYR61/TAL1/CALCRL/ACVRL1/ENG/ANXA3/NR4A1/SEMA5A/HYAL1/EDN1/CX3CL1
GO: 0010632	Regulation of epithelial cell migration	4.99E-06	TEK/EPB41L5/MAP3K3/MMRN2/ETS1/PTPRM/DCN/PRKCE/SASH1/MACF1/TGFBR2/SLIT2/GATA2/MEOX2/EMP2/RAB11A/ANGPT1/STARD13/KDR/FGF2/FGF18/CLASP2/PPM1F/BMP2/PTPRG/ACVRL1/ANXA3/SEMA5A/HYAL1/EDN1
GO: 0090130	Tissue migration	5.52E-06	TEK/EPB41L5/KANK2/MAP3K3/MMRN2/ETS1/PTPRM/DCN/FOXF1/PRKCE/SASH1/MACF1/TGFBR2/SLIT2/GATA2/MEOX2/EMP2/RAB11A/ANGPT1/STARD13/KDR/FGF2/PECAM1/ZEB2/FGF18/CLASP2/PPM1F/BMP2/PTPRG/ACVRL1/ANXA3/NR4A1/SEMA5A/HYAL1/EDN1
GO: 0010631	Epithelial cell migration	6.36E-06	TEK/EPB41L5/KANK2/MAP3K3/MMRN2/ETS1/PTPRM/DCN/PRKCE/SASH1/MACF1/TGFBR2/SLIT2/GATA2/MEOX2/EMP2/RAB11A/ANGPT1/STARD13/KDR/FGF2/PECAM1/ZEB2/FGF18/CLASP2/PPM1F/BMP2/PTPRG/ACVRL1/ANXA3/NR4A1/SEMA5A/HYAL1/EDN1
GO: 0090132	Epithelium migration	6.36E-06	TEK/EPB41L5/KANK2/MAP3K3/MMRN2/ETS1/PTPRM/DCN/PRKCE/SASH1/MACF1/TGFBR2/SLIT2/GATA2/MEOX2/EMP2/RAB11A/ANGPT1/STARD13/KDR/FGF2/PECAM1/ZEB2/FGF18/CLASP2/PPM1F/BMP2/PTPRG/ACVRL1/ANXA3/NR4A1/SEMA5A/HYAL1/EDN1
GO: 1904018	Positive regulation of vasculature development	2.78E-05	TEK/MAP3K3/TMEM100/ETS1/RAP1A/CFLAR/PPP1R16B/CX3CR1/SASH1/TGFBR2/AGTR1/GATA2/GATA6/KDR/CDH5/FGF2/HGF/FGF18/PRKCB/ACVRL1/ENG/ANXA3/SEMA5A/HYAL1/CX3CL1
GO: 1901888	Regulation of cell junction assembly	3.69E-05	ARHGAP6/TEK/EPB41L5/DLC1/LIMCH1/RAP1A/PEAK1/MACF1/KDR/GPM6B/CLASP2/PPM1F/CAV1/ACVRL1/PRKCH/ACE/CLDN5
GO: 2000146	Negative regulation of cell motility	3.69E-05	RGN/DLC1/MMRN2/PTPRM/ADARB1/LIMCH1/TBX5/SMAD7/RECK/DCN/CX3CR1/LRCH1/PRKG1/SLIT2/MEOX2/CXCL12/STARD13/SCAI/IL33/FGF2/PTGER4/CLASP2/PTPRG/MMP28/FBLN1/DUSP1/ACVRL1/ENG/PPARGC1A/NAV3/CX3CL1
GO: 0051271	Negative regulation of cellular component movement	3.94E-05	RGN/DLC1/MMRN2/PTPRM/ADARB1/LIMCH1/TBX5/SMAD7/RECK/DCN/CX3CR1/LRCH1/PRKG1/SLIT2/MEOX2/CXCL12/STARD13/SCAI/IL33/FGF2/PTGER4/TGFBR3/CLASP2/PTPRG/MMP28/FBLN1/DUSP1/ACVRL1/ENG/PPARGC1A/NAV3/SEMA5A/CX3CL1
GO: 1901342	Regulation of vasculature development	3.94E-05	TEK/MAP3K3/MMRN2/TMEM100/ETS1/PTPRM/RAP1A/CFLAR/PPP1R16B/DCN/CX3CR1/SASH1/NPR1/TGFBR2/AGTR1/GATA2/GATA6/MEOX2/PDE3B/EMP2/KLF2/STARD13/KDR/CDH5/FGF2/HGF/FGF18/PRKCB/ACVRL1/ENG/ANXA3/SEMA5A/HYAL1/CX3CL1

**Table S2** The KEGG analysis

ID	Description	P adjust	Gene ID
Up-regulated			
hsa03440	Homologous recombination	2.08E-04	<i>BRIP1/BRCA2/BLM/EME1/RPA3/BRCA1</i>
hsa00240	Pyrimidine metabolism	1.07E-03	<i>NME1/TYMS/DTYMK/TK1/RRM2/DCTPP1</i>
hsa04914	Progesterone-mediated oocyte maturation	1.72E-02	<i>CCNA2/MAD2L1/AURKA/CCNB1/BUB1/CCNB2</i>
hsa03030	DNA replication	9.69E-06	<i>RNASEH2A/POLE2/MCM2/RPA3/FEN1/MCM4/RFC4</i>
hsa04115	p53 signaling pathway	7.90E-05	<i>GTSE1/CCNE1/CCNB1/RRM2/CDKN2A/CCNE2/CCNB2/CHEK1</i>
hsa04218	Cellular senescence	2.23E-03	<i>CCNE1/CCNA2/CCNB1/CDKN2A/CCNE2/CCNB2/CHEK1/FOXM1/MYBL2</i>
hsa03460	Fanconi anemia pathway	5.58E-08	<i>BRIP1/FANCI/FANCD2/BRCA2/BLM/EME1/RPA3/RMI2/BRCA1/UBE2T</i>
hsa04114	Oocyte meiosis	7.90E-05	<i>CCNE1/PTTG1/ESPL1/MAD2L1/AURKA/CCNB1/CCNE2/CDC20/BUB1/CCNB2</i>
hsa05166	Human T-cell leukemia virus 1 infection	2.94E-04	<i>BUB1B/CCNE1/PTTG1/CCNA2/ESPL1/MAD2L1/SLC2A1/CDKN2A/CCNE2/CDC20/CCNB2/FGFR1OP</i>
hsa04110	Cell cycle	1.68E-11	<i>BUB1B/CCNE1/PTTG1/CCNA2/MCM2/ESPL1/MAD2L1/CCNB1/CDKN2A/CCNE2/CDC20/BUB1/TTK/CCNB2/FGFR1OP/MCM4/BRIP1</i>
Down-regulated			
hsa04270	Vascular smooth muscle contraction	1.41E-03	<i>MYH11/PRKCE/GUCY1A2/NPR1/AGTR1/PRKG1/CACNA1D/PLA2G1B/ADCY4/PRKCB/EDNRA/PPP1R12B/CALCRL/PPP1R14A/PRKCH/EDN1</i>
hsa04924	Renin secretion	1.58E-03	<i>ADRB2/GUCY1A2/NPR1/AGTR1/CACNA1D/PDE3B/PTGER4/EDNRA/ADRB1/ACE/EDN1</i>
hsa04514	Cell adhesion molecules (CAMs)	6.26E-03	<i>JAM2/PTPRM/ITGA8/CADM1/JAM3/CDH5/ITGAL/PECAM1/ESAM/CLDN18/ICAM2/HLA-E/SELPLG/NFASC/CLDN5</i>
hsa04022	cGMP-PKG signaling pathway	6.26E-03	<i>ADRB2/ATP1A2/PRKCE/GUCY1A2/NPR1/AGTR1/PRKG1/CACNA1D/PDE3B/PDE5A/ADCY4/EDNRB/PIK3R5/TRPC6/EDNRA/ADRB1</i>
hsa04670	Leukocyte transendothelial migration	1.41E-02	<i>JAM2/RAP1A/JAM3/CXCL12/CDH5/ITGAL/PECAM1/ITK/PRKCB/ESAM/CLDN18/CLDN5</i>

**Table S3** The top 5 GO biological terms of each cluster

Cluster	ID	Description	P adjust
Cluster 1	GO: 0007059	Chromosome segregation	1.01E-13
	GO: 0140014	Mitotic nuclear division	1.01E-13
	GO: 0000280	Nuclear division	2.81E-12
	GO: 0048285	Organelle fission	6.48E-12
	GO: 0000070	Mitotic sister chromatid segregation	2.40E-11
Cluster 2	GO: 0007059	Chromosome segregation	1.01E-13
	GO: 0140014	Mitotic nuclear division	1.01E-13
	GO: 0000280	Nuclear division	2.81E-12
	GO: 0048285	Organelle fission	6.48E-12
	GO: 0000070	Mitotic sister chromatid segregation	2.40E-11
Cluster 3	GO: 0035589	G protein-coupled purinergic nucleotide receptor signaling pathway	0.021666
	GO: 0035590	Purinergic nucleotide receptor signaling pathway	0.021986
	GO: 0035588	G protein-coupled purinergic receptor signaling pathway	0.021986
	GO: 0050921	Positive regulation of chemotaxis	0.021986
	GO: 0050927	Positive regulation of positive chemotaxis	0.021986
Cluster 4	GO: 0010389	Regulation of G2/M transition of the mitotic cell cycle	5.27E-09
	GO: 1902749	Regulation of cell cycle G2/M phase transition	7.15E-09
	GO: 0000086	G2/M transition of the mitotic cell cycle	1.91E-08
	GO: 0044839	Cell cycle G2/M phase transition	3.41E-08
	GO: 0000226	Microtubule cytoskeleton organization	7.26E-08
Cluster 5	GO: 0000209	Protein polyubiquitination	0.000605
	GO: 0043687	Post-translational protein modification	0.066311
	GO: 0006511	Ubiquitin-dependent protein catabolic process	0.096811
	GO: 0019941	Modification-dependent protein catabolic process	0.096811
Cluster 6	GO: 0000280	Nuclear division	3.10E-07
	GO: 0048285	Organelle fission	3.10E-07
	GO: 0140014	Mitotic nuclear division	9.30E-07
	GO: 0051301	Cell division	9.30E-07
	GO: 0030261	Chromosome condensation	9.69E-07
Cluster 7	GO: 0007188	Adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1.83E-08
	GO: 0019932	Second-messenger-mediated signaling	1.83E-08
	GO: 0007187	G protein-coupled receptor signaling pathway coupled to cyclic nucleotide second messenger	1.91E-08
	GO: 0019935	Cyclic-nucleotide-mediated signaling	4.95E-07
	GO: 0007189	Adenylate cyclase-activating G protein-coupled receptor signaling pathway	2.60E-06

**Table S4** The logFC and P adjust of six hub genes in the datasets

Datasets	GSE18842		GSE19188		GSE27262		GSE33532	
	LogFC	P adjust	LogFC	P adjust	LogFC	P adjust	LogFC	P adjust
BUB1B	4.73	1.92E-36	3.61	8.79E-32	3.37	1.58E-12	3.87	7.69E-17
CCNB1	4.72	4.17E-41	3.81	7.10E-35	3.17	1.11E-12	4.33	2.31E-22
CENPE	3.39	8.97E-37	2.61	1.04E-27	1.58	1.30E-05	2.77	1.55E-11
KIF18A	2.27	1.02E-18	1.57	7.68E-14	1.47	1.95E-06	1.59	4.44E-08
MAD2L1	4.64	1.61E-37	2.98	2.10E-22	2.81	7.32E-12	3.79	1.88E-14
NDC80	3.64	3.92E-32	3.17	1.12E-27	2.54	2.79E-09	3.78	2.17E-16